G1 Therapeutics Inc

NASDAQ:GTHXUnited States

G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. The Company's lead compound COSELA (trilaciclib), is a therapy designed to help protect hematopoietic stem and progenitor cells (HSPCs) in bone marrow against chemotherapy-induced myelosuppression by transiently inhibiting CDK4/6 in patients with extensive-stage small cell lunger cancer (ES-SCLC). Its Lerociclib, is a differentiated clinical-stage oral CDK4/6 inhibitor for use in combination with other targeted therapies in multiple oncology indications. The Company's Rintodestrant, is a clinical-stage oral selective estrogen receptor degrader (SERD), for use as a monotherapy and in combination with CDK4/6 inhibitors, initially Ibrance (palbociclib), for the treatment of estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 (HER2)-breast cancer.

Contact Information

Headquarters

700 Park Offices Drive, Suite 200RESEARCH TRIANGLE PARK, NC, United States 27709

Phone

919-213-9835

Fax

919-741-5830

Executives

Independent Chairman of the Board

Garry Nicholson

President, Chief Executive Officer, Director

John Bailey

Chief Financial Officer

Jennifer Moses

Chief Operating Officer

Terry Murdock

General Counsel, Corporate Secretary

James Hanson